ADC Review / Journal of Antibody-drug Conjugates

By InPress Media Group | ADC Review / Journal of Antibody-drug Conjugates (ISSN: 2327-0152) is an international peer reviewed publication. Key information includes peer-reviewed articles, news features, discussions, blogs, and a knowledge center offering the latest and most relevant information about Antibody Drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments.

London Calling: The Cutting-edge of Novel ADC Technologies

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual ADC …

Antibodies

Antibody Drug Conjugates News

01 August, 2017<p>Seattle Genetics has agreed to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in the North Creek area of …

Medicine

Early Detection: The New Cancer Paradigm

<i>A seemingly healthy patient walks into the doctor’s office for a routine checkup. The doctor says: “I have good news and bad news. The bad news is</i> …

Cancer

Contract Manufacturing of Antibody-drug Conjugates – A Growing Market

The demand for manufacturing capacity of antibody-drug conjugates (ADCs), which includes a highly potent cytotoxic drug linked to a monoclonal …

Developing the Next Generation of Clinically Successful Antibody-drug Conjugates

Since the approval of the first antibody-drug conjugate or ADC, now more than 15 years ago, scientists and researchers have sent more than 50 ADCs to …

Medicine

Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament

Earlier this month, during the <i>57th Annual Meeting and Exposition of the American Society of Hematology (ASH)</i>, held in Orlando, Florida from December …

Cancer

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19 Positive B-cell Non-Hodgkin Lymphomas

Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary antibody-drug …

Cancer

Commercial and Regulatory Progress under Brentuximab Vedotin Collaboration Between Seattle Genetics and Takeda

Nearly 7 years ago, in 2009, Seattle Genetics, a clinical stage biopharmaceutical company, and Takeda Pharmaceuticals, Japan’s largest pharmaceutical …

Cancer

Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies – Moves to Phase I

Lymphomas, a group of cancers that originate in the lymphatic system, include both <i>Hodgkin lymphoma</i> (HL) and <i>non-Hodgkin lymphoma</i> (NHL). Non-Hodgkin …

Cancer

Synaffix’s New High Potency Lab now Fully Operational to Support Growing Collaboration With Biotech and Pharma

Late last week, Synaffix, a Dutch biotechnology company backed by a top tier, life science-focused, investor syndicate and the strategic corporate …

Pharma

Vadastuximab Talirine (SGN-CD33A) Combination Therapy Evaluates Safety and Activity for Patients with Untreated Myelodysplastic Syndrome

A new phase I/II clinical trial of vadastuximab talirine, also known as SGN-CD33A; 33A (Seattle Genetics), in combination with <i>azacitidine</i> (Vidaza®; …

Strategic Collaboration Between CMC Biologics and IDT Biologika to Manufacture Antibody Drug Conjugates

Denmark-based CMC Biologics, a company involved in the clinical and commercial manufacturing of monoclonal antibodies and other therapeutic proteins, …

Medicine

First Patient Dosed in Phase I Trial of ADCT-301 Trial

Earlier this month ADC Therapeutics, a Swiss-based oncology drug development company, dosed the first patient in a Phase I trial to evaluate …

Cancer

Sacituzumab Govitecan Receives Breakthrough Therapy Designation for Triple-negative Breast Cancer

The investigational antibody-drug conjugate, sacituzumab govitecan, also know as IMMU-132 (Immunomedics), has received Breakthrough Therapy …

Cancer

Study Links Gemtuzumab Ozogamicin Response in Pediatric AML to Expression Level of CD33

Expression CD33 is largely restricted to hematopoietic cells. [1] Because CD33 is consistently expressed on <i>acute myeloid leukemia</i> or AML blasts, it …

Cancer

Breakthrough Therapy Designation for Sacituzumab Govitecan in Triple-negative Breast Cancer

Sacituzumab govitecan, also known as IMMU-132, has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the …

Cancer

Piramal Expands Coldstream Laboratories’ ADC Capacity

Piramal Pharma Solutions has confirmed that it is planning an expansion Coldstream Laboratories, its sterile injectable manufacturer the company …

Pharma

Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based Antibody-Drug Conjugates

Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic partnership. Under the …

Cancer

Survival Benefit of Ado-trastuzumab Emtansine in Heavily Pretreated HER2+ Breast Cancer Patients Confirmed in Various Studies

Study results from the phase III TH3RESA clinical trial presented during the 38th San Antonio Breast Cancer Symposium (SABCS) held in San Antonio in …

Cancer

Advancements in Bispecific Antibody Immunotherapy Development

The 15th annual <i>Cambridge Healthcare Institute’s PepTalk – Protein Science Week</i>, one of the largest gatherings of protein science researchers in the …

Medicine

European Commission Approves Label Variation for Brentuximab Vedotin

The European Commission (EC) has, earlier this week, approved a Type II variation for brentuximab vedotin (Adcetris®; Takeda/Seattle Genetics) to …

Cancer

Blinatumomab Shows Positive Outcomes in Acute Lymphoblastic Leukemia

Data presented during the 57th Annual Meeting and Exposition of the <i>American Society of Hematology</i> (ASH) in Orlando, Florida shows that Amgen’s …

Cancer

Pfizer Exercises Options As Part of License Agreement with Philogen

Swiss-Italian Philogen, a clinical-stage biotechnology company engaged in the discovery and development of novel biopharmaceutical products, has …

Pfizer

CytomX Therapeutics and Bristol-Myers Squibb Continue Collaboration

CytomX Therapeutics, an oncology-focused biopharmaceutical company based in South San Francisco developing investigational Probody™ therapeutics for …

Cancer

Lonza Expands it’s Mammalian Production Capacity

Over the last decade, biologics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), therapeutic proteins, immunotherapeutics, …

Manufacturing

Roche and Catalent Start Research Collaboration on SMARTAG™ Technology

New Jersey based Catalent has agreed to a research collaboration with Roche to develop next-generation molecules coupling different therapeutic …

Hips

Targeting Breast Cancer with more Punch

To optimize current treatment and develop methods to more efficiently treat breast cancer, scientists have been researching molecules that …

Cancer

Immunomedics Receives U.S. patent for Labetuzumab Govitecan

Earlier this week Immunomedics announced the issuance of U.S. patent no. 9,226,973 for additional claims. Under the patent family “<i>Dosages of</i> …

Cancer

Sacituzumab Govitecan Continues to show Positive Results in the Treatment of Heavily Pre-treated Metastatic Triple-Negative Breast Cancer Patients

Updated results from a Phase II clinical study of sacituzumab govitecan, also known as IMMU-132, in patients with metastatic triple-negative breast …

Cancer